Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Biogen Idec

MS franchise continues growth trend

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Biogen Idec 4Q/FY

4Q Revenues: $1.4 billion (+7%)

4Q Earnings: $292 million (-3%)

FY Revenues: $5.5 billion (+9%)

FY Earnings: $1.4 billion (+9%)

Comments: Tysabri sales rose 5% for the year to $1.1 billion, while Avoenx revenues rose 8% to $2.9 billion in that span. For 4Q12, Tysabri was up 10% to $295 million and Avonex sales were up7% to $753 million. Revenues from other products rose 67% for the year. R&D expenses rose slightly in 4Q to $345 million, and were $1.3 billion for the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics